Contineum Therapeutics Files 8-K

TL;DR

Contineum Therapeutics filed an 8-K on Dec 11, 2025, for events on Dec 8, 2025. Standard financial/exhibit filing.

AI Summary

Contineum Therapeutics, Inc. filed an 8-K on December 11, 2025, reporting on events that occurred on December 8, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.

Why It Matters

This filing indicates Contineum Therapeutics is providing updated financial statements and exhibits to the SEC, which is standard procedure for public companies.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any new material adverse events or significant financial changes.

Key Players & Entities

• Contineum Therapeutics, Inc. (company) — Registrant
• Pipeline Therapeutics, Inc. (company) — Former company name
• December 8, 2025 (date) — Earliest event reported date
• December 11, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — tered Class A Common Stock , par value $0.001 per share CTNM The Nasdaq Global Mar

Filing Documents

• ctnm20251204_8k.htm (8-K) — 32KB
• 0001437749-25-037547.txt ( ) — 165KB
• ctnm-20251208.xsd (EX-101.SCH) — 3KB
• ctnm-20251208_def.xml (EX-101.DEF) — 12KB
• ctnm-20251208_lab.xml (EX-101.LAB) — 15KB
• ctnm-20251208_pre.xml (EX-101.PRE) — 12KB
• ctnm20251204_8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This 8-K contains "forward-looking statements" of the Company within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the potential of the data from the Company's Phase 1 clinical trials to predict the tolerability, safety or dose selection and strategy for the Phase 2 clinical trial of PIPE-791 in IPF, the potential treatment impact of PIPE-791 and the success and timing of our clinical development strategies and plans to conduct our clinical trial of PIPE-791 in various countries globally, the estimated trial completion date for the Phase 2 clinical trial of PIPE-791 in IPF. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's clinical development programs, collaboration with third parties, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals for our clinical trial protocol and ultimate regulatory approval for PIPE-791, the ability of the Company to successfully develop PIPE-791, the Company's ability to achieve its projected development goals in its expected timeframes, the risk that results from earlier trials may not be predictive of future trial results, risks related to adverse side effects, risks related to reliance on third party partners to conduct certain activities on the Company's behalf, smaller than anticipated market opportunities for the Company's products and product candidates, manufacturing risks, competition from other therapies or products, and other matters that could affect the sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the Company's future operating results and fin

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 11, 2025 Contineum Therapeutics, Inc. By: /s/ Peter Slover Peter Slover Chief Financial Officer Principal Financial Officer and Principal Accounting Officer

View Full Filing

View this 8-K filing on SEC EDGAR